We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
-1.02%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$10.5B
AUM Growth
-$388M
(-3.6%)
Cap. Flow
-$87.6M
Cap. Flow
% of AUM
-0.84%
Top 10 Holdings %
Top 10 Hldgs %
14.73%
Holding
713
New
186
Increased
183
Reduced
156
Closed
168
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSH
Marsh
MRSH
|
+$120M |
| 2 |
Chord Energy
CHRD
|
+$106M |
| 3 |
Electronic Arts
EA
|
+$96.9M |
| 4 |
Quest Diagnostics
DGX
|
+$89.2M |
| 5 |
Sensata Technologies
ST
|
+$76.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Analog Devices
ADI
|
+$138M |
| 2 |
Avnet
AVT
|
+$130M |
| 3 |
ERF
Enerplus Corporation
ERF
|
+$110M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$73.5M |
| 5 |
Honeywell
HON
|
+$72.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.43% |
| 2 | Technology | 19.78% |
| 3 | Energy | 7.84% |
| 4 | Industrials | 7.21% |
| 5 | Financials | 7.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Cabaletta Bio
CABA
$437M
| $1.82M | 0.02% |
242,981
+318
| +0.1% | +$3.9K |
|
427
Rhythm Pharmaceuticals
RYTM
$6.81B
| $1.82M | 0.02% |
44,247
-127,960
| -74% | -$5.11M |
|
428
Zura Bio
ZURA
$516M
| $1.81M | 0.02% |
+515,899
| New | +$2.1M |
|
429
Relay Therapeutics
RLAY
$4.1B
| $1.78M | 0.02% |
273,616
+608
| +0.2% | +$4.15K |
|
430
Eledon Pharmaceuticals
ELDN
$261M
| $1.78M | 0.02% |
675,243
+23,304
| +4% | +$55.6K |
|
|
KALV
431
DELISTED
KalVista Pharmaceuticals
KALV
| $1.77M | 0.02% |
150,462
| – | – |
|
|
LBPH
432
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.74M | 0.02% |
64,438
-16,482
| -20% | -$325K |
|
|
SLN
433
Silence Therapeutics
SLN
$495M
| $1.73M | 0.02% |
90,862
-147,518
| -62% | -$3.14M |
|
|
XOMA
434
DELISTED
Xoma
XOMA
| $1.71M | 0.02% |
72,211
+105
| +0.1% | +$2.63K |
|
|
RGLS
435
DELISTED
Regulus Therapeutics
RGLS
| $1.69M | 0.02% |
+947,685
| New | +$2.2M |
|
436
Neumora Therapeutics
NMRA
$298M
| $1.61M | 0.02% |
+164,160
| New | +$1.7M |
|
|
BOW
437
Bowhead Specialty Holdings
BOW
$1B
| $1.57M | 0.02% |
+62,000
| New | +$1.58M |
|
438
MacroGenics
MGNX
$235M
| $1.57M | 0.02% |
369,542
+4,117
| +1% | +$40.1K |
|
439
Aquestive Therapeutics
AQST
$464M
| $1.56M | 0.01% |
600,959
+367
| +0.1% | +$1.23K |
|
440
TransDigm Group
TDG
$70.2B
| $1.5M | 0.01% |
1,171
-28,861
| -96% | -$37M |
|
441
Knowles
KN
$3.13B
| $1.48M | 0.01% |
85,550
-206,205
| -71% | -$3.46M |
|
442
Tyra Biosciences
TYRA
$1.9B
| $1.42M | 0.01% |
+88,656
| New | +$1.53M |
|
443
Workiva
WK
$3.36B
| $1.37M | 0.01% |
18,762
+13,975
| +292% | +$1.1M |
|
444
Stoke Therapeutics
STOK
$1.8B
| $1.35M | 0.01% |
100,182
-6,722
| -6% | -$90.8K |
|
445
Alto Neuroscience
ANRO
$1.05B
| $1.34M | 0.01% |
125,000
| – | – |
|
446
Braze
BRZE
$2.81B
| $1.33M | 0.01% |
34,173
+25,090
| +276% | +$1M |
|
447
Denali Therapeutics
DNLI
$3.65B
| $1.31M | 0.01% |
56,554
-452,011
| -89% | -$8.68M |
|
|
LSXMA
448
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $1.18M | 0.01% |
53,341
-145,306
| -73% | -$3.46M |
|
449
PTC
PTC
$15.8B
| $1.18M | 0.01% |
+6,501
| New | +$1.16M |
|
450
Regenxbio
RGNX
$620M
| $1.17M | 0.01% |
100,000
-46,334
| -32% | -$721K |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2024 Portfolio in Review
As of Q2 2024, Woodline Partners held 713 positions worth $10.5B, down 3.6% from $10.9B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners's Q2 2024 filing shows 186 new, 183 increased, 156 reduced and 168 closed positions. Its largest new stake was Marsh: 585,204 shares worth $123M. The largest sale was Analog Devices, an estimated $138M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Energy.
- Woodline Partners's largest Q2 2024 buy was Marsh: 585,204 shares worth $123M.
- Woodline Partners added most to Chord Energy in Q2 2024, an estimated $106M increase.
- Woodline Partners's biggest Q2 2024 reduction was Avnet, cutting an estimated $130M.
- Woodline Partners fully exited Analog Devices in Q2 2024, selling an estimated $138M.
- Woodline Partners's ten largest holdings make up 15% of its $10.5B portfolio in Q2 2024.
- Woodline Partners opened 186 new positions and closed 168 in Q2 2024.
- Woodline Partners's portfolio value fell 3.6% quarter-over-quarter to $10.5B.
Based on Woodline Partners's 13F filing for Q2 2024, filed 14 Aug 2024.